Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Therapeutic Targeting of Long Non-Coding RNAs in Cancer.

Literature DB >> 29449148

Therapeutic Targeting of Long Non-Coding RNAs in Cancer.

Gayatri Arun¹, Sarah D Diermeier¹, David L Spector².

Abstract

Long non-coding RNAs (lncRNAs) represent a significant population of the human transcriptome. Many lncRNAs exhibit cell- and/or tissue/tumor-specific expression, making them excellent candidates for therapeutic applications. In this review we discuss examples of lncRNAs that demonstrate the diversity of their function in various cancer types. We also discuss recent advances in nucleic acid drug development with a focus on oligonucleotide-based therapies as a novel approach to inhibit tumor progression. The increased success rates of nucleic acid therapeutics provide an outstanding opportunity to explore lncRNAs as viable therapeutic targets to combat various aspects of cancer progression.

Entities: Chemical

Mesh：

Substances：

Year: 2018 PMID： 29449148 PMCID： PMC5840027 DOI： 10.1016/j.molmed.2018.01.001

Source DB: PubMed Journal: Trends Mol Med ISSN： 1471-4914 Impact factor: 15.272

202 in total

1. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs.

Authors: Yvonne Tay; Lev Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi
Journal: Cell Date: 2011-10-14 Impact factor: 41.582

2. 3S: shotgun secondary structure determination of long non-coding RNAs.

Authors: Irina V Novikova; Ashutosh Dharap; Scott P Hennelly; Karissa Y Sanbonmatsu
Journal: Methods Date: 2013-08-06 Impact factor: 3.608

Review 3. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.

Authors: Daniel J Rader; John J P Kastelein
Journal: Circulation Date: 2014-03-04 Impact factor: 29.690

4. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a.

Authors: Kyoko L Yap; Side Li; Ana M Muñoz-Cabello; Selina Raguz; Lei Zeng; Shiraz Mujtaba; Jesús Gil; Martin J Walsh; Ming-Ming Zhou
Journal: Mol Cell Date: 2010-06-11 Impact factor: 17.970

5. A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells.

Authors: Fabio Petrocca; Gabriel Altschuler; Shen Mynn Tan; Marc L Mendillo; Haoheng Yan; D Joseph Jerry; Andrew L Kung; Winston Hide; Tan A Ince; Judy Lieberman
Journal: Cancer Cell Date: 2013-08-12 Impact factor: 31.743

6. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.

Authors: David Hong; Razelle Kurzrock; Youngsoo Kim; Richard Woessner; Anas Younes; John Nemunaitis; Nathan Fowler; Tianyuan Zhou; Joanna Schmidt; Minji Jo; Samantha J Lee; Mason Yamashita; Steven G Hughes; Luis Fayad; Sarina Piha-Paul; Murali V P Nadella; Morvarid Mohseni; Deborah Lawson; Corinne Reimer; David C Blakey; Xiaokun Xiao; Jeff Hsu; Alexey Revenko; Brett P Monia; A Robert MacLeod
Journal: Sci Transl Med Date: 2015-11-18 Impact factor: 17.956

10. Systematic analysis identifies three-lncRNA signature as a potentially prognostic biomarker for lung squamous cell carcinoma using bioinformatics strategy.

Authors: Jing Hu; Lutong Xu; Tao Shou; Qiang Chen
Journal: Transl Lung Cancer Res Date: 2019-10

Therapeutic Targeting of Long Non-Coding RNAs in Cancer.

1. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs.

2. 3S: shotgun secondary structure determination of long non-coding RNAs.

Review 3. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.

4. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a.

5. A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells.

6. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.

7. Antisense Oligonucleotide-mediated Knockdown in Mammary Tumor Organoids.

8. A cluster of noncoding RNAs activates the ESR1 locus during breast cancer adaptation.

9. Pan-cancer transcriptome analysis reveals long noncoding RNAs with conserved function.

10. Widespread RNA binding by chromatin-associated proteins.

1. Role of LINC00152 in non-small cell lung cancer.

2. In Vitro Silencing of lncRNAs Using LNA GapmeRs.

Review 3. Long non-coding RNAs: the tentacles of chromatin remodeler complexes.

4. ERINA Is an Estrogen-Responsive LncRNA That Drives Breast Cancer through the E2F1/RB1 Pathway.

5. Emerging roles of long non-coding RNAs in the p53 network.

Review 6. Long noncoding RNA loss in immune suppression in cancer.

Review 7. The Role of Non-coding RNAs in Oncology.

8. Long noncoding RNA, LINC00460, as a prognostic biomarker in head and neck squamous cell carcinoma (HNSCC).

Review 9. Identifying targets for preventing epilepsy using systems biology of the human brain.

10. Systematic analysis identifies three-lncRNA signature as a potentially prognostic biomarker for lung squamous cell carcinoma using bioinformatics strategy.